values; and (3) goodness of fit (Hosmer-Lemeshow). The model was then used to develop a risk-score chart. Results A model was developed using variables for which there was a significant relationship. Variables included were systolic blood pressure, fasting glucose, C-reactive protein, blood urea nitrogen, and alcohol consumption. The model performed well, and no significant differences were observed when utilized in the validation datasets. A risk score was developed, and the probability of developing MA for each score was calculated. Conclusion The predictive model provides new evidence about variables related with MA and may be used by clinicians to identify at-risk patients and to tailor treatment. The risk score developed may allow clinicians to measure a patient's MA risk.
Introduction
As the cost of healthcare rises, health programs face the challenge of providing suitable services while controlling expenses. One way to address this problem is to identify patients with special needs and enroll them in tailored care plans [1] . A promising tool that could be used to promote this goal is predictive modeling, in which retrospective patient data are analyzed and used to create algorithms that can determine the likelihood of future events [2, 3] . In the case of healthcare, predictive models can improve efficiency, reduce administrative costs, and allow providers to better tailor patient care [4] . While predictive models have been used for decades in other industries, they have only recently been employed in the healthcare sector [5, 6] .
Microalbuminuria (MA) is the presence of albumin above the normal level but below the detection limit of simple assays. A condition commonly encountered in urological and nephrological practice [7] , MA is a consequence of altered glomerular permeability, which could be the result of pathophysiological events such as hypertension or diabetes mellitus [8] [9] [10] . Recent studies have shown that MA may be associated with an increased risk of cardiovascular events and mortality [11, 12] . Furthermore, MA has been identified as a marker of organ damage, such as left ventricular hypertrophy and atherosclerosis, and as a predictor of hypertension and diabetes complications [13] .
Despite recent evidence for these clinical implications, there is little information regarding which patient variables, such as demographics and comorbidities, are related with the presence of MA. The objectives of this study are (1) to develop a patient data-driven predictive model and a riskscore assessment to improve the identification of MA and MA risk; and (2) to validate the performance of the predictive model to identify patients at risk of MA.
Methods

Study design
A retrospective database study was conducted and predictive model created using data from the 2007-2008 National Health and Nutrition Examination Survey (NHANES), which contains a series of cross-sectional health examination data and is conducted in mobile investigation units or healthcare settings. This survey includes representative data pertaining to the nutritional and health status of the American population and includes data on diet, biochemical tests, physical measurements, and clinical assessments.
For the purpose of this study, the database was divided into thirds, one of which was utilized to create the predictive model and the other two to internally validate the model. The database was partitioned without replacement, meaning each observation appeared only once in each utilized portion. An external validation was also performed using the 2012-2013 NHANES database.
MA was defined in this study as an albumin excretion rate within the range of 30-299 mg of albumin/g of creatinine [7] . This ratio-the albumin/creatinine ratio (ACR)-was used as the dependent variable in this study in light of recently published evidence that ACR exhibited a higher sensitivity and specificity in the detection of MA in different groups of patients [14] .
Variables under consideration to be included in the predictive model were chosen based on evidence in the literature linking them to the presence of MA. These variables were drawn from three categories: (1) patient demographic variables, such as age, gender, race, marital status, income/ socioeconomic status, health insurance, occupation, education; (2) patient medical variables, such as diagnoses and comorbidities (e.g., presence of diabetes, obesity, cardiovascular disease, liver disease, renal disease), number of visits, medication, body mass index, smoking status, alcohol intake, drug use, medical history, clinical symptoms, allergies, adverse events; and (3) patient laboratory test/ physical examination variables, including blood pressure, serum triglycerides, total cholesterol, blood uric acid, blood urea nitrogen (BUN), serum creatinine concentrations, fasting plasma glucose, HbA1c levels, albuminuria, and C-reactive protein (CRP). The study included only variables that were available in the NHANES database and that could be obtained in routine clinical practice.
Modeling process
Descriptive statistics were used to summarize the predictor variables. Differences between the variables in the model creation database and the model validation database were analyzed using unpaired Student's t tests for continuous variables and Chi-square tests for categorical variables. Univariate and multivariate logistic regression analyses were conducted to assess correlation between variables and to select the final variables for inclusion in the stepwise logistic regression equation model used to predict the probability of developing MA. Correlations with a p value <0.05 were considered statistically significant. All statistical analyses were performed using STATA statistical software, version 11.2 (StataCorp, College Station, Texas, USA).
Model performance, calibration, and discrimination
Pseudo-R 2 was calculated to evaluate the overall performance of the model. The Hosmer-Lemeshow "goodnessof-fit" (GOF) test was used to quantify the calibration of the model. Pearson's Chi-square was applied to compare observed counts with expected counts. A significant result for the Hosmer-Lemeshow (p value <0.05) signified a lack of fit. The area under the receiver operating characteristic (ROC) curve was used to quantify the discrimination of the model, corresponding to the likelihood that the outcome studied (MA) will have a higher predicted probability (Y = 1) than a non-event (ranging from zero to one), which accounts for the model's ability to discriminate between those patients who experience MA versus those who do not. In this study, an area under the curve (AUC) ≤0.5 signified no discrimination; AUC of 0.6-0.69 signified poor discrimination; AUC of 0.7-0.8 signified acceptable discrimination; and AUC of 0.8-0.9 signified excellent discrimination.
Risk score
The multivariable model generated to predict the occurrence of MA contained regression coefficients representing the weights of variables that were significantly associated with MA. To facilitate the use of the model in clinical practice and to minimize confusion in the mathematical calculation, a risk score was calculated using these coefficients and following the approach proposed by Sullivan et al. [15] Variables were organized into categories, and reference values were determined. A score was assigned for each variable and its category.
Validation
Cross-validation is a statistical technique used to assess how the results of a model would generalize to an independent dataset. Internal validation of the model was conducted using the remaining two-thirds of the 2007-2008 NHANES database, while external validation of the model was conducted using data from 2012-2013 NHANES database. A ROC curve and confidence interval were calculated for each database portion to assess the performance of the proposed model.
Results
Of the 10,149 patients in the third of the 2007-2008 NHANES database utilized for model development, 2271 were excluded from the study because they lacked data on urine albumin and/or urine creatinine, which are needed to calculate the albumin/creatinine ratio (ACR). For the remaining 7878 patients included in the development sample, the prevalence of MA was 12.6 %, with a considerably higher incidence in female participants (14 %) than males (11 %; p value <0.001). This difference was also identified in the validation datasets. In the model development dataset, patients with micro-and macroalbuminuria (clinical albuminuria) were older than those with normal albuminuria values. Variables with significantly higher values in subjects classified with microalbuminuria were: systolic blood pressure (SBP), glycohemoglobin (HbA1c), serum glucose, triglycerides, creatinine in serum and urine, C-reactive protein (CRP), uric acid and blood urea nitrogen (BUN).
According to the correlation analysis, the variables positively and significantly correlated with microalbuminuria included: sex, age, SBP, mean arterial pressure, glycosylated hemoglobin, glucose serum, triglycerides, serum creatinine, CRP, albumin urine, globulin, BUN, and lactate dehydrogenase. Variables negatively and significantly correlated with microalbuminuria included: alcohol consumption, creatinine urine, estimated glomerular filtration rate, and albumin serum.
All variables with a significant positive or negative correlation were included in the modeling process, for which a multivariate logistic model was built using stepwise selection. In this step, variables withp values of <0.05 were considered to be significantly associated with the presence of microalbuminuria. For analyses of MA occurrence, four models were estimated using the best performing subsets. The most parsimonious model (Table 1) included as final variables: fasting glucose level, CRP, SBP, BUN, and alcohol consumption. This model was selected to predict microalbuminuria because of its capacity to fit the data: GOF test of 0.667, its area under the curve (ROC) of 0.78 [95 % CI 0.73-0.84], and a pseudo-R 2 of 0.21, as well as for its potential for to be easily implemented in common clinical practice.
An equation was created based on the coefficients of the multivariate logistic regression model. In the equation, fasting glucose was entered as mg/dL, CRP as mg/dL, SBP as mmHg, BUN as mg/dL, and moderate alcohol consumption as yes (=1) or no (=0). This equation calculates the probability of developing microalbuminuria.
Risk score
To facilitate the calculation of a patient's risk of microalbuminuria in clinical practice, a risk score was developed. Alcohol consumption was excluded from the risk-score calculation because of its lack of specificity. Assignment
of score points was based on organizing each variable into clinically meaningful intervals. The midpoint of each interval was assigned as the reference value for that interval. In the case of intervals with no lower limit, the midpoint between the first percentile value of the dataset and the upper bound of the interval was assigned as the reference value, and in intervals with no upper bound, the midpoint between the lower bound of the interval and the 99th percentile value of the dataset was assigned as the reference value.
Once reference values were assigned, a beta coefficient for each interval was calculated by subtracting the zeroscore-assigned reference value from each interval's reference value. This number was then multiplied by the beta coefficient of the variable determined from the model. To standardize the beta coefficients, each was divided by 0.224, the beta coefficient with the lowest value from the model. The closest integer or 0.5 value of this resulting quotient was then chosen to be the score for that interval. For example, the SBP range of 130-139 mmHg includes the reference value of 135. The beta coefficient for this reference value is 0.32 which was then divided by 0.224 to obtain a value of 1.43. This value was then rounded to 1.5 (the closest integer or 0.5 value). Therefore, a patient with a SBP in this range would be assigned 1.5 points for the SBP variable. Scores for each of the other intervals for each variable were calculated using the same method. The sum of all of these scores was 18. However, some intervals (below the most normal zero-assigned range) were assigned negative values. Therefore, a subject could obtain a final score anywhere between −5 and 18 (Table 2 ) [15] [16] [17] .
Each patient's final risk score was determined by summing the scores for each of the patient's variables. This final risk score corresponds to a probability of developing MA. These probabilities (Table 3) were obtained by plugging median dataset values for each variable into the model equation, excluding alcohol consumption, and including the equation's constant. Scores below zero were not included in Table 3 ; however, it should be understood that if a patient has a final risk score less than zero, then that patient's predicted probability of developing microalbuminuria is <7.9 %.
Validation
The final step of this study was to evaluate the performance of the model. Internal validity was evaluated using the validation portion of the 2007-2008 NHANES dataset (twothirds of the full dataset). External validation was evaluated using the 2012-2013 NHANES dataset. To do this, the coefficients generated by each model were inputted in a vector of coefficients and tested (Table 4 ). Figure 1 shows the ROC curves comparing the model performance with the development and validation dataset.
Discussion
Few models have been proposed to identify subjects at risk of suffering microalbuminuria, and no models have used general population data or a retrospective database to do so. As a consequence, the models that do exist have limited application and are restricted to subjects with defined characteristics. These models were constructed using narrow inclusion criteria and include some but not all traditional demographic, cardiovascular, metabolic, and other potential risk factors. As a consequence, they focus on a very specific portion of the population.
In this study, however, a more representative American population was used. The proposed model captured variables that, for this dataset, represent the best approximation of variables acting together can predict the occurrence of microalbuminuria; however, given the retrospective nature of the data, it is not possible to establish a causal relationship. Furthermore, the model cannot account for 100 % of microalbuminuria occurrence. Nevertheless, the findings generally agree with those of previous studies. A study conducted in 2012 by Mongkolsomlit et al. [16] included diabetic subjects in one Thai hospital. The researchers collected patient variables (e.g., age, gender, body mass index, glycemic control, blood pressure, dyslipidemia) through a case-control study design. The model identified duration of diabetes, systolic blood pressure, creatinine, and alcohol consumption as independent predictors of microalbuminuria. Despite these findings, the authors identified several limitations, including a small sample size and limited generalizability to other clinical settings and populations.
Another study conducted in 2013 by Scheven et al. [18] included 5000 subjects who attended control appointments once every 3 years for 9 years. During each appointment, anthropometrical and clinical variables were collected. The investigators identified age, male gender, higher BMI, and albuminuria at baseline, but not systolic blood pressure or higher plasma glucose, as predictors of progressive albuminuria. When the authors removed albuminuria at baseline from the model, they found systolic blood pressure and plasma glucose to be predictors of progressive albuminuria.
In the Framingham offspring cohort from 2002, baseline albuminuria, age, male gender, diabetes mellitus, cholesterol, and smoking were associated with the occurrence of microalbuminuria [19] . Like other studies, this one focused on investigating the factors associated with microalbuminuria in diabetic subjects, a group that may not be generalizable to the general population. Microalbuminuria is usually absent at diagnosis for type 1 diabetes but could be present at diagnosis for type 2 diabetes, whose diagnosis is often delayed [20] . Risk of occurrence of microalbuminuria is directly related with the level and duration of hyperglycemia and is higher in subjects with poor hyperglycemic control and who have had a diabetes diagnoses for more than 5 years. Aggressive glycemic control prevents albuminuria onset and progression, demonstrating that hyperglycemia over the course of several years is a cause of microalbuminuria [21] .
Ritz et al. [22] also demonstrated that intensive lowering of blood glucose in subjects with diabetes prevents the onset and progression of microalbuminuria. Mechanisms of glucose-related albuminuria have been discussed by the Satchell study, but involved glomerular hyperperfusion and hyperfiltration because of the lack of selectivity in glomerular membrane [23] . Meigs et al. [21] found that elevations in baseline and 24-year time fasting glucose were strongly associated with microalbuminuria, meaning that subjects for whom type 2 diabetes developed over 24 years were most likely to have microalbuminuria. This association was independent of age and elevated systolic blood pressure.
In the construction of the predictive model in this study, systolic blood pressure was included as a predictor of microalbuminuria. Its effect is similar to that described in models using a prospective cohort. Microalbuminuria may be more frequent in subjects with moderate to severe hypertension, and less frequent in subjects with uncomplicated hypertension. Screening for microalbuminuria in hypertensive subjects can be easily integrated into clinical practice and can inform treatment decisions.
A study by Pascual et al. [24] assessed the development of microalbuminuria in a population with low cardiovascular risk and untreated mild hypertension. The results demonstrated that elevated systolic blood pressure precedes the occurrence of microalbuminuria, suggesting that proper control of blood pressure and maintaining a fasting glucose level within a normal range could prevent the occurrence of microalbuminuria.
The determination of serum blood urea nitrogen (BUN) is the most widely used screening test to evaluate kidney function. Eghan et al. [25] in a cross-sectional study including diabetes subjects found that BUN, among other variables, was a predictor of microalbuminuria. Zakerdish et al. found in a study that albuminuria in diabetes subjects is correlated with BUN level, HbA1c, and duration of diabetes mellitus; however, no model was proposed to calculate the probability of subjects developing microalbuminuria [26] Two other models proposed by Scheven et al. [18] and by Mongkolsomlit et al. [16] did not consider the inclusion of BUN measures in the development of their corresponding models.
C-reactive protein (CRP) is one of the markers of subclinical inflammation and is thought to represent chronic low-grade inflammation of the arterial walls [27] . CRP has been identified as a novel cardiovascular risk factor, and its presence is related with injury at the endothelial level. Microalbuminuria has been identified not only as an indicator for early kidney impairment [28] , but also as a risk factor for progressive renal disease and cardiovascular morbidity [29] . Studies have indicated that CRP is related with microalbuminuria in diabetic [30] and hypertensive subjects [31] . A study conducted by Sabanayagam et al. [32] found that when combining data from two Asian cohorts, CRP level was significantly associated with microalbuminuria and this association was independent of age, sex, alcohol consumption, smoking status, and blood pressure. Furthermore, the relationship was preserved when CRP was analyzed as either a categorical or continuous variable and when the two cohorts were analyzed separately.
In Mojahedi et al. [33] CRP was independently related to the occurrence of microalbuminuria. In type 2 diabetic subjects, microalbuminuria was accompanied by high CRP levels, suggesting activation of inflammatory pathways in the progression of renal and cardiovascular atherosclerotic disease. This model was the first to include CRP as a predictor of microalbuminuria and a variable utilized to calculate the probability of microalbuminuria. CRP has not been included in a formal predictive model, but it has been associated with the presence of microalbuminuria in many univariate studies.
The differences between the model proposed in this research and those in the literature mainly involve inclusion criteria, the characteristics of the subjects, and the availability of variables. Furthermore, the model proposed in this investigation uses a different data source (retrospective dataset) and includes a broader population. The internal and external validation of this dataset showed a good discriminative performance of the model. It is necessary to mention that other confounding variables could affect protein excretion and therefore influence the occurrence of microalbuminuria in certain populations. This is one of the limitations to consider within our study because it was not possible to obtain more exhaustive information about the population: such as number of years subjects were hypertensive and their pharmacological treatment. Another limitation is that the use of a single Alb/ Cr ratio may have misclassified the albuminuria status of some subjects since this ratio is known to vary from day to day and could be increased by fever, urinary tract infection, exercise, etc. Because this study utilized observational data, it is not possible to determine causality even with multivariate analyses that concurrently control for several variables to estimate the independent effect of each variable on the presence of microalbuminuria.
Despite these limitations, the model created in this study included variables that can be easily obtained by physical examinations and laboratory tests. Therefore, this approach is an inexpensive tool for healthcare professionals and perhaps epidemiologists to identify subjects at risk of microalbuminuria. This information can assist clinicians to stratify their patients by risk, facilitate appropriate treatment of patients regarding prognosis, and possibly influence the intensity of follow-up care and medical management.
Conclusion
Microalbuminuria has been a popular research focus in recent years, and a method that can identify the factors or predictors involved in the development of this condition may provide a better understanding of microalbuminuria and the variables involved in its development. Arguably all cardiovascular risk factors are in some way related to the occurrence of microalbuminuria. However, the strength and variance of these relationships are unknown. Accordingly, this study offers valuable information that may lead to a better understanding of the variables involved in the development of microalbuminuria, a well-established indicator of cardiovascular and renal disease.
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